ArticleJournal of orthopaedic surgery and research2025
Regulating osteogenic differentiation of bone marrow mesenchymal stem cells by mTORC1 signaling pathway inhibits bone defect repair in mice.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBone defects caused by traumatic injuries and orthopedic diseases have emerged as the most common challenges in contemporary orthopedics, characterized by treatment difficulty, long treatment time, and high economic costs. This study aims to demonstrate that the activated mTOR pathway in mesenchymal stromal cells regulates the bone repair process.
methodsInitially, the mammalian target of rapamycin (mTOR) pathway-activated mouse model was constructed by specifically knocking down the tuberous sclerosis complex 1 (TSC1) molecule in bone marrow mesenchymal stem cells (BMMSCs). Then, the differences in bone repair between transgenic mice and littermate control mice in a single-layer cortical bone defect model were evaluated by histological, immunohistochemical, and micro-CT analyses. Further, the effects of the mTOR pathway on the osteoinductive differentiation ability of BMMSCs and its mechanism were mainly verified by cellular osteogenic staining and Western blotting experiments.
resultsThe activated mTORC1 in mesenchymal stromal cells during bone defect repair in mice inhibited not only the healing rate of bone but also their ability to differentiate into osteoblasts, resulting in a decrease in the number of osteoblasts. The ability of mTORC1 in mesenchymal stromal cells to regulate osteoblastic differentiation might be related to the NOTCH pathway.
conclusionThe activated mTOR pathway during bone defect repair could inhibit the osteogenic ability of BMMSCs and hinder the bone healing process. Accordingly, regulating the activation of the mTOR pathway might promote the repair of bone defects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.